EBRO 2017

How to combine… chemotherapy and RT

Study

Type of study

n. pts Inclusion criteria

RT (Gy)

Type of CT

Main Results

Kumar et al

Phase I 22

IR- HR 70.2

Docetaxel

G2 diarrhea = 36% G2 dysuria = 23%

Chen et al

Phase I 18

HR

78 (IMRT) Docetaxel

Median FUP 26 mo bRFS = 94%. Median FUP 41 mo bRFS = 80%. No severe tox.

Marchall et al Phase I 19

HR

77.4

Docetaxel

Sanfilippo et al

Phase I- II

22

HR

63-73.8 Dose escalation

Paclitaxel

Six of the twenty-two patients experienced a PSA relapse at a median follow-up of 38 mo

Perrotti et al

Phase I-II

20

HR

72 (IMRT) Docetaxel

3 G3 acute tox